In vitro effects of estradiol, Dydrogesterone (cas 152-62-5), tamoxifen and cyclophosphamide on proliferation vs. death in human breast cancer cells

Add time:09/28/2019    Source:infona.pl

The effects of 17β-estradiol, dihydrodydrogesterone, tamoxifen and cyclophosphamide upon parameters of cell maturation (Mucine1 expression), cell proliferation (Cyclin D1 expression) and apoptosis (loss of nuclear DNA) were studied in estrogen receptor positive (ER+) and negative (ER−) human breast cancer cells. Tamoxifen was the most potent inducer of apoptosis in ER+ and ER− breast cancer cells. 17β-estradiol in a concentration of 10−6 M induced proliferation in ER+ cells after 144 h. incubation, while equimolar co-incubation with dihydrodydrogesterone prevented this effect and even induced a significant increase of cell death. It is speculated that the continuous use of combined 17β-estradiol plus dihydrodydrogesterone might be given as hormone replacement therapy without increased risk of breast cancer and even may reduce the relapse rate in breast cancer patients.

We also recommend Trading Suppliers and Manufacturers of Dydrogesterone (cas 152-62-5). Pls Click Website Link as below: cas 152-62-5 suppliers

Prev:Immobilized Heterologous Rhizopus Oryzae Lipase as an Efficient Catalyst in the Acetylation of CORTEXOLONE (cas 152-58-9)
Next:Assessment of sub‐endometrial blood flow parameters following Dydrogesterone (cas 152-62-5) and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: A pilot study)